Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

uch statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and de
'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  Neogen Corporation (Nasdaq: NEOG ... quarter of its 2015 fiscal year, which ended Aug. ... net income of $7,839,000 in the first quarter of ... Oct. 30, 2013, earnings per share in the current ... First quarter revenues increased 15% to $67,599,000, ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
(Date:9/21/2014)... September 21, 2014 Chemical Sciences ... challenges such as clean air and safe water, ... natural products. Chemists, environmentalists, food scientists, educators, and ... research in the field of Chemistry for the ... Sciences is one of the fastest emerging Sciences, ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Inc. (PDL, the Company) (NASDAQ: PDLI ) today ... other conditions, $135 million aggregate principal amount of new convertible ... statement filed with the U.S. Securities and Exchange Commission (SEC) ... the underwriters a 13-day overallotment option to purchase up to ...
... SPRING, Md., May 9, 2011 The U.S. Food and ... public relating to the development of a user fee ...   (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... as a microorganism, plant, or animal cell, while small ...
... 2011 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that the U.S. Securities and Exchange ... Statement relating to the previously announced acquisition of TomoTherapy ... registration statement will first be mailed to TomoTherapy shareholders ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 4
(Date:9/22/2014)... fishes that manufacture their own "antifreeze" proteins to ... an unfortunate side effect, researchers report: The protein-bound ... melting even when temperatures warm. , The ... the National Academy of Sciences . , "We ... of the evolution of antifreeze proteins in Antarctic ...
(Date:9/22/2014)... 2014)The Brain & Behavior Research Foundation ... Young Investigator Grants valued at more than ... most promising young scientists. Recipients of the ... will seek to identify causes, improve treatments ... that affect one in four people, including ...
(Date:9/22/2014)... more useful in homes, if they could locate people, ... with cameras and lasers, which have difficulty reliably recognizing ... clutter. A complementary way robots can "sense" what is ... frequency radio-frequency identification (UHF RFID) tags. Inexpensive self-adhesive tags ... to search a room for the correct tag,s signal, ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... Karen Burg and her colleagues in the Institute for ... means of studying the complex behavior of cancer cells ... way doctors treat the disease. With support from ... the researchers are building scaffolds that mimic the three-dimensional ...
... diseases is a hot area of scientific research, primarily ... the context of atherosclerotic disease. Scientists have engineered a ... about the conditions under which nanoparticles accumulate in the ... of myocardial infarction and stroke. In the research, ...
... blood platelets and bone marrow cells to deliver potentially ... genetic disorder Hurler syndrome an often fatal condition ... Scientists from Cincinnati Children,s Hospital Medical Center and the ... their unique strategy for treating the disease the week ...
Cached Biology News:In vitro innovation: Testing nanomedicine with blood cells on a microchip 2In vitro innovation: Testing nanomedicine with blood cells on a microchip 3Mouse study shows gene therapy may be possible cure for Hurler syndrome 2
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
DNA fragmentation factor & Inhibitor of CAD...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Biology Products: